Pharmacology of new aromatase inhibitors

被引:76
作者
Lonning, PE
机构
关键词
D O I
10.1016/S0960-9776(96)90094-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent investigations of novel aromatase inhibitors have addressed several important questions related to the biochemical effects of this class of drugs. While aromatase inhibitors such as aminoglutethimide, formestane (given by the oral and i.m. route), rogletimide and fadrozole administered at different doses have been found to inhibit in vivo aromatization by 60-93%, the novel aromatase inhibitors, letrozole and anastrozole, are shown to inhibit in vivo aromatization by about 98%. Contrary to previous studies on aromatase inhibitors reporting plasma oestrogens sustained at 30-50% of their control levels letrozole and anastrozole suppress plasma oestrone sulphate by approximately 95%. Future studies should explore cross-resistance of aromatase inhibitors and steroidal antioestrogens and between different types of aromatase inhibitors. A major goal is to evaluate alterations in tissue oestrogen concentration as well as growth factor expression in response to oestrogen deprivation with aromatase inhibitors.
引用
收藏
页码:202 / 208
页数:7
相关论文
共 45 条
[1]   AMINOGLUTETHIMIDE IN ADVANCED BREAST-CANCER - CLINICAL-RESULTS OF A FRENCH MULTICENTER RANDOMIZED TRIAL COMPARING 500 MG AND 1 G/DAY [J].
BONNETERRE, J ;
COPPENS, H ;
MAURIAC, L ;
METZ, M ;
ROUESSE, J ;
ARMAND, JP ;
FARGEOT, P ;
MATHIEU, M ;
TUBIANA, M ;
CAPPELAERE, P .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (10) :1153-1158
[2]   LOW-DOSE AMINOGLUTETHIMIDE WITHOUT HYDROCORTISONE FOR THE TREATMENT OF ADVANCED POSTMENOPAUSAL BREAST-CANCER [J].
BRUNING, PF ;
BONFRER, JMG ;
HART, AAM ;
VANDERLINDEN, E ;
DEJONGBAKKER, M ;
MOOLENAAR, AJ ;
NOOIJEN, WJ .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (02) :369-376
[3]   BENEFICIAL RESPONSE TO PITUITARY ABLATION FOLLOWING AMINOGLUTETHIMIDE [J].
BUNDRED, NJ ;
EREMIN, O ;
STEWART, HJ ;
DALE, BA ;
FORREST, APM .
BRITISH JOURNAL OF SURGERY, 1986, 73 (05) :388-389
[4]   4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER [J].
COOMBES, RC ;
GOSS, P ;
DOWSETT, M ;
GAZET, JC ;
BRODIE, A .
LANCET, 1984, 2 (8414) :1237-1239
[5]   EFFECTS OF FADROZOLE (CGS-16949A) AND LETROZOLE (CGS-20267) ON THE INHIBITION OF AROMATASE-ACTIVITY IN BREAST-CANCER PATIENTS [J].
DEMERS, LM .
BREAST CANCER RESEARCH AND TREATMENT, 1994, 30 (01) :95-102
[6]   AROMATIZATION INHIBITION ALONE OR IN COMBINATION WITH GNRH AGONISTS FOR THE TREATMENT OF PREMENOPAUSAL BREAST-CANCER PATIENTS [J].
DOWSETT, M ;
STEIN, RC ;
COOMBES, RC .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1992, 43 (1-3) :155-159
[7]   POTENCY AND SELECTIVITY OF THE NONSTEROIDAL AROMATASE INHIBITOR CGS 16949A IN POSTMENOPAUSAL BREAST-CANCER PATIENTS [J].
DOWSETT, M ;
STEIN, RC ;
MEHTA, A ;
COOMBES, RC .
CLINICAL ENDOCRINOLOGY, 1990, 32 (05) :623-634
[8]  
Dowsett M, 1995, CLIN CANCER RES, V1, P1511
[9]  
DOWSETT M, 1989, CANCER RES, V49, P1306
[10]   Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects [J].
Geisler, J ;
Johannessen, DC ;
Anker, G ;
Lonning, PE .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (05) :789-792